9RP Stock Overview
Develops drugs for lipid related diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Lipigon Pharmaceuticals AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0087 |
| 52 Week High | SEK 0.028 |
| 52 Week Low | SEK 0.0001 |
| Beta | 0.91 |
| 1 Month Change | 8,600.00% |
| 3 Month Change | 8,600.00% |
| 1 Year Change | -72.98% |
| 3 Year Change | -98.43% |
| 5 Year Change | n/a |
| Change since IPO | -99.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9RP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 19.2% | -3.2% | 2.7% |
| 1Y | -73.0% | -7.9% | 17.0% |
Return vs Industry: 9RP underperformed the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: 9RP underperformed the German Market which returned 17% over the past year.
Price Volatility
| 9RP volatility | |
|---|---|
| 9RP Average Weekly Movement | 3,003.6% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9RP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9RP's weekly volatility has increased from 1519% to 3004% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6 | Stefan Nilsson | www.lipigon.se |
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia.
Lipigon Pharmaceuticals AB (publ) Fundamentals Summary
| 9RP fundamental statistics | |
|---|---|
| Market cap | €2.13m |
| Earnings (TTM) | -€1.97m |
| Revenue (TTM) | €799.25k |
2.7x
P/S Ratio-1.1x
P/E RatioIs 9RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9RP income statement (TTM) | |
|---|---|
| Revenue | SEK 8.97m |
| Cost of Revenue | SEK 23.76m |
| Gross Profit | -SEK 14.79m |
| Other Expenses | SEK 7.32m |
| Earnings | -SEK 22.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | -164.87% |
| Net Profit Margin | -246.49% |
| Debt/Equity Ratio | 0% |
How did 9RP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 22:11 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipigon Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |